Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Moving on
View:
Post by scarlet1967 on May 13, 2021 1:14pm

Moving on

Ovarian cancer: Setback as major screening trial fails to save lives

Ovarian cancer: Setback as major screening trial fails to save lives

TH1904 seems to be targeting ovarian cancer as per google,:

“The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.”

Comment by juniper88 on May 13, 2021 2:07pm
The difference between TH1902 and TH1904 is the payload, nothing else.  Yes, Thera initially used TH1904 (doxorubicin payload) to for the preclinical ovarian cancer work.  But then they used TH1902 (docetaxol payload) and found it actually worked better on ovarian cancer. than TH1904. Sortilin receptor seems to be higher expressed as the disease gets to a later stage and the higher the ...more  
Comment by realitycheck4u on May 13, 2021 2:33pm
This post has been removed in accordance with Community Policy
Comment by scarlet1967 on May 13, 2021 2:37pm
Sorry to hear about your wife's struggles but I am glad she responded well to the treatment. I think OHIP should cover the cost of a life saving treatment, it's absolutely disgraceful! I am not sure about whether TH1902 could be used as a maintenance treatment indefinitely but I came across another study which indicated the PDC technology can potentially treat metastatic TNB cancer so ...more  
Comment by scarlet1967 on May 13, 2021 2:45pm
https://www.mdpi.com/1422-0067/22/9/4673
Comment by scarlet1967 on May 13, 2021 3:21pm
I posted this earlier the article goes on also suggesting combination therapies as another approach to bypass the MDR. This article published yesterday emphasized the urgent need for a targeted drug therapy such as PDC for among others metastatic breast cancer due to multidrug resistance, Thus far a combination of anticancer drugs has been used as standard chemotherapy treatment although this ...more  
Comment by qwerty22 on May 13, 2021 3:01pm
To add to what you say. You could imagine that if sortilin is a major mechanism for aggressiveness and plasticity in cancer cells then th1902 might be perfectly suited for clearing up those pesky cells that escape tumours and cause re-occurrence as in your wife's case, as you say it could be well suited to maintainance with a nice tolerability profile. The possibilities are endless (which ...more  
Comment by Wino115 on May 13, 2021 3:17pm
Thank you for the insights.  Most of all, I hope the treatment works.  Any thoughts of trialing the TH1902 if it shows decent results?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities